Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Bispecific mosunetuzumab shows promise in R/R follicular lymphoma and DLBCL

Ian Flinn • 2 Dec 2018
ASH 2018
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Mosunetuzumab

Speaking the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, held in San Diego, CA, Ian Flinn, MD, PhD, of the Tennessee Oncology, Nashville, TN, discusses the CD20/CD3-directed antibody mosunetuzumab in relapsed/refractory B-cell lymphoma (Phase I; NCT02500407). Dr Flinn highlights the promise of this off-the-shelf bispecific antibody.

More from Ian Flinn

2:18
SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
Ian Flinn • 9 Dec 2021
0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals